Latest news with #Woburn
Associated Press
a day ago
- Business
- Associated Press
Fortune 100 Tech Enterprise Signs Retainer Agreement with HawkSearch
Retainer agreement will optimize global search and recommendation experiences WOBURN, MASSACHUSETTS / ACCESS Newswire / July 30, 2025 / Bridgeline Digital, Inc. (NASDAQ:BLIN), a leader in AI-powered marketing technology, announced today that a Fortune 100 global technology company has signed a retainer agreement with HawkSearch to power its eCommerce search engine. The engagement will focus on optimizing site search performance across the client's global web properties, using HawkSearch's AI-driven capabilities to deliver more relevant, personalized search results at scale. With global teams, complex product catalogs, and evolving user needs, enterprise brands require search technology that adapts at scale. HawkSearch delivers this with AI-powered relevance tuning, multilingual support, and flexible integration across platforms, making it an ideal solution for Fortune 100 organizations managing high-volume, multi-region digital experiences. 'This retainer agreement reflects HawkSearch's strength in delivering long-term value to enterprise brands,' said Ari Kahn, CEO of Bridgeline. 'We're excited to support this client's digital evolution with the flexibility and focus a retainer model provides.' About Bridgeline Bridgeline helps companies grow online revenue by increasing traffic, conversion rates, and average order value. To learn more, visit . Contact: Danielle Colvin SVP of Marketing Bridgeline Digital [email protected] SOURCE: Bridgeline Digital press release
Yahoo
07-07-2025
- Business
- Yahoo
Sirtex Medical's SIR-Spheres® Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable Hepatocellular Carcinoma
Expanded indication makes SIR-Spheres® the first and only radioembolization therapy in the U.S. approved to treat both unresectable hepatocellular carcinoma and metastatic colorectal cancer WOBURN, Mass., July 7, 2025 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of interventional oncology solutions, today announced that the U.S. Food and Drug Administration (FDA) approved SIR-Spheres® Y-90 resin microspheres for the treatment of unresectable hepatocellular carcinoma (HCC) in the United States. With this approval, SIR-Spheres® is the only radioembolization therapy approved for the treatment of both metastatic colorectal cancer (mCRC) of the liver and HCC in the U.S. HCC is the most common form of liver cancer in adults in the U.S., according to the American Cancer Society. Radioembolization–commonly referred to as selective internal radiation therapy (SIRT)–with SIR-Spheres® uses personalized dosimetry to deliver the optimal dose of radiation directly to tumors in patients with HCC. This approval gives clinicians expanded flexibility in selecting a liver-directed therapy that aligns with patient-specific needs and treatment goals. "The expanded indication makes SIR-Spheres® the only Y-90 treatment approved in the U.S. for both HCC and mCRC," said Matt Schmidt, CEO of Sirtex. "This milestone reflects our ongoing commitment to delivering flexible, personalized therapies—with multiple dose options available daily—that empowers physicians to treat patients when and where it works best." This regulatory milestone is supported by results from the DOORwaY90 study, a prospective, multicenter, open-label clinical trial evaluating the safety and efficacy of SIR-Spheres® in treating HCC. The study enrolled 100 patients across 18 U.S. centers, with 65 patients included in the interim primary efficacy cohort. DOORwaY90 met its prespecified co-primary endpoints, demonstrating a best overall response rate (ORR) of 98.5% as assessed by independent central review. All evaluable patients demonstrated a response, indicating a 100% local tumor control rate. Additionally, the median duration of response (DoR) exceeded 300 days. These findings highlight SIR-Spheres® as a highly effective liver-directed therapy with a favorable safety profile. "This study moves the field of radioembolization forward with reproducible dosimetry outcomes and a strong safety profile linked to very positive clinical results," said Dr. Armeen Mahvash, Interventional Radiologist at MD Anderson Cancer Center and Co-Principal Investigator of the DOORwaY90 Study. "This will give multidisciplinary care teams the confidence to recommend SIR-Spheres® for HCC treatment." For more information and details on how to incorporate SIR-Spheres® into your practice, please contact Sirtex at info-use@ About SIR-Spheres®SIR-Spheres® Y-90 resin microspheres are indicated for the local tumor control of unresectable hepatocellular carcinoma (HCC) in patients with no macrovascular invasion, Child-Pugh A cirrhosis, well-compensated liver function, and good performance status. They are also indicated for the treatment of unresectable metastatic liver tumors from primary colorectal cancer with adjuvant intra-hepatic artery chemotherapy (IHAC) of FUDR (Floxuridine). Caution: Federal (USA) law restricts this device for sale by or on the order of a physician. Consult the Instructions for Use ( for a complete listing of indications, contraindications, side effects, warnings and precautions. About SirtexSirtex Medical is a global healthcare company focused on advancing minimally invasive, liver-directed cancer and embolization therapies. With offices in the U.S., Australia, Europe, and Asia, Sirtex delivers innovative interventional oncology and embolization solutions to physicians and patients worldwide. The company's lead product, SIR-Spheres® Y-90 resin microspheres, is now the only FDA approved product in the United States indicated for both the treatment of hepatocellular carcinoma (HCC) and metastatic colorectal cancer (mCRC). For more information, visit APM-US-010-06-25 View original content: SOURCE Sirtex Medical Inc. Sign in to access your portfolio
Associated Press
03-07-2025
- Business
- Associated Press
HawkSearch Named #1 in Gartner(R) 2025 Critical Capabilities for Search and Product Discovery Report in the B2B Search Use Case
WOBURN, MA / ACCESS Newswire / July 3, 2025 / Bridgeline Digital, Inc. (NASDAQ:BLIN), a leader in AI-driven marketing technology, announced today that HawkSearch has been ranked #1 in the 2025 Gartner® Critical Capabilities Report in the B2B Search Use Case. HawkSearch has been identified as #1 in the 2025 Gartner® Critical Capabilities Report in the B2B Search Use Case. Gartner delivers actionable, objective insight to executives and their teams. Its expert guidance and tools enable faster, smarter decisions and stronger performance on an organization's mission-critical priorities. 'We believe this recognition reaffirms HawkSearch's goal of delivering precision and efficiency in digital product discovery for manufacturers, distributors, and wholesalers,' said Ari Kahn, CEO of Bridgeline. 'To us, the Gartner recognition highlights HawkSearch's unmatched performance in handling complex B2B search from part number/SKU recognition and unit-of-measure conversions to customer-level entitlements, targeted personalization and AI-powered search. HawkSearch solves the real-world search needs B2B companies face every day. From finding exact part numbers to handling multiple units of measure, we build intelligent solutions that simplify complex buying journeys.' HawkSearch continues to serve as a critical technology partner to major B2B brands. HP Inc. relies on HawkSearch to drive product discovery across its global eCommerce presence, enabling highly personalized customer experiences and supporting significant transactional volume. Some of the largest electrical distributors in the U.S. use HawkSearch across hundreds of localized webstores, streamlining B2B purchasing and increasing efficiency for contractors and procurement teams. Gartner, Critical Capabilities for Search and Product Discovery, By Aditya Vasudevan, Mike Lowndes, Noam Dorros, Sandy Shen, 24 June 2025 GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved. Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. About Bridgeline Bridgeline helps companies grow online revenue by increasing traffic, conversion rates, and average order value. To learn more, visit . Contact: Danielle Colvin SVP of Marketing Bridgeline DigitalSOURCE: Bridgeline Digital press release
Associated Press
19-06-2025
- Business
- Associated Press
Leading Electrical Distributor Selects HawkSearch to Power Unified Enterprise Search Across Over 70 Sites
Unified AI-powered search connects products, content, and events to grow revenue WOBURN, MA / ACCESS Newswire / June 19, 2025 / Bridgeline Digital Inc. (NASDAQ:BLIN), a leader in AI-driven marketing technology, announced today that a national electrical distributor has chosen HawkSearch to power a unified AI search experience across more than 70 digital storefronts. The electrical distributor integrates HawkSearch with Sitecore CMS and Salesforce Commerce Cloud to create a unified search that supports product discovery, content navigation, and event promotion. Unified search powered by AI ensures users find the most relevant results across all systems, from products to events, in a single experience. With HawkSearch, searching for 'EV charging accessories' can receive relevant results from multiple sources, such as product listings, related blog content, installation guides, and upcoming webinars, regardless of where the content is stored. This improves discovery, shortens the buyer journey, and creates a cohesive digital experience across all storefronts, which ultimately drives more revenue. 'This deployment highlights HawkSearch's ability to unify search across multiple complex digital environments,' said Ari Kahn, CEO of Bridgeline. 'We're excited to help this distributor create a more powerful and personalized search experience.' About Bridgeline Digital Bridgeline helps companies grow online revenue by increasing traffic, conversion rates, and average order value. To learn more, visit . Contact: Danielle Colvin SVP of Marketing Bridgeline Digital [email protected] SOURCE: Bridgeline Digital press release
Associated Press
03-06-2025
- Business
- Associated Press
Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book
WOBURN, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), today announced the inclusion of the patent for its propylene glycol-free formulation of Ameluz® nanoemulsion gel in the US Food and Drug Administration's (FDA's) publication 'Approved Drug Products with Therapeutic Equivalence Evaluations' (commonly known as the Orange Book). The Orange Book is a key reference for healthcare providers, pharmacists, and payers and is the definitive source for identifying FDA-approved drug products. Inclusion of a drug in the Orange Book confirms that the FDA recognizes that the drug meets their rigorous standards for safety, efficacy, and quality. In addition, patents listed confer intellectual property protections which may include the drug's composition, formulation, or specific uses. Listing of the patent for the propylene glycol-free formulation of Ameluz® prevents generic competition as long as the patent is valid, which currently is December 2043. The revised formulation, which eliminates propylene glycol—a well-known allergen for some patients1—demonstrates Biofrontera's continued commitment to innovation and patient-centric development. It offers a significant improvement for individuals who are sensitive to this excipient without compromising the treatment's effectiveness. The patent for the revised formulation of Ameluz® was issued on April 22, 2025, and lasts until December 8, 2043. The formulation itself was accepted by the FDA and has been in use since 2024. 'We are proud to announce the inclusion of the patent for our propylene glycol-free formula in the Orange Book,' said Dr Hermann Luebbert, CEO and Chairman of Biofrontera Inc. 'This recognition validates the differentiated profile of our propylene glycol-free formulation, offering physicians and patients a formulation that reduces the potential for allergic reactions while maintaining the efficacy of Ameluz® RhodoLED PDT.' References: About Biofrontera Inc. Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz® with the RhodoLED® lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit and follow Biofrontera on LinkedIn and Twitter. Forward-Looking Statements Certain statements in this press release may constitute 'forward-looking statements' within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended. These statements include, but are not limited to, statements relating to Biofrontera's commercial opportunities and the commercial success of its licensed products. We have based these forward-looking statements on our current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: the impact of any extraordinary external events; any changes in the Company's relationship with its licensors; the ability of the Company's licensors to fulfill their obligations to the Company in a timely manner; the Company's ability to achieve and sustain profitability; whether the current global disruptions in supply chains will impact the Company's ability to obtain and distribute its licensed products; changes in the practices of healthcare providers, including any changes to the coverage, reimbursement and pricing for procedures using the Company's licensed products; the uncertainties inherent in the initiation and conduct of clinical trials; availability and timing of data from clinical trials; whether results of earlier clinical trials or trials of Ameluz® in combination with BF-RhodoLED and/or RhodoLED XL in different disease indications or product applications will be indicative of the results of ongoing or future trials; uncertainties associated with regulatory review of clinical trials and applications for marketing approvals; whether the market opportunity for Ameluz in combination with BF- RhodoLED and/or RhodoLED XL is consistent with the Company's expectations; the Company's ability to retain and hire key personnel; the sufficiency of cash resources and need for additional financing; and other factors that may be disclosed in the Company's filings with the Securities and Exchange Commission (the 'SEC'), which can be obtained on the SEC's website at Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law. Contact: Investor Relations Andrew Barwicki 1-516-662-9461 [email protected]
